SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

The health sector is navigating various challenges, including debates over drug pricing in the EU, pest agreements between ...

MIDVALE, Utah (AP) — MIDVALE, Utah (AP) — Utah Medical Products Inc. (UTMD) on Tuesday reported net income of $3 million in its first quarter. On a per-share basis, the Midvale, Utah-based company ...

A German pharmaceutical company is acquiring a drug developer with operations in Research Triangle Park.

LIMA, Peru (AP) — LIMA, Peru (AP) — Cementos Pacasmayo SAA (CPAC) on Monday reported profit of $14.2 million in its first quarter. The Lima, Peru-based company said it had profit of 16 cents per share ...

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

Novartis released a more optimistic full-year earnings forecast on Tuesday, citing the strong growth of drugs such as Leqvio, ...

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...

Fintel reports that on April 28, 2025, Barclays downgraded their outlook for SpringWorks Therapeutics (NasdaqGS:SWTX) from ...

The loans sat on banks' books for two-and-a-half years until the election of Donald Trump rapidly changed the company's fortunes. International Business Machines plans to invest $150 billion in the ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.